The Industry

April 2010
Pharmaceutical Representative;Apr2010, Vol. 40 Issue 4, p7
The article offers world news briefs on the pharmaceutical industry. Daiichi Sankyo Co. Ltd. is expected to generate an operating profit of 138 billion yens on revenue of 1.06 trillion yens in 2013, according to Thomson Reuters. OSI Pharmaceuticals Inc. rejected the 3.5 billion dollar cash offered by Astellas. Transgene Inc. signed an exclusive option agreement with Novartis for the development and commercialization of TG4010 (MVA-MUC1-IL2), a first-line treatment of non-small cell lung cancer.


Related Articles

  • Biota/Daiichi Oral Flu Vaccine Clears Hurdles.  // Bioworld Week;8/17/2009, Vol. 17 Issue 33, p3 

    The article reports that business partners Biota Holdings Ltd. and Daiichi Sankyo Co. Ltd. have confirmed the positive results in the Phase III development of the antiviral flu drug laninamivir, and have planned for the commercialization of the drug in the U.S. Daiichi claims that a single...

  • Daiichi Sankyo Paying $235M For U3's Oncology Pipeline. Sheridan, Cormac // BioWorld International;5/28/2008, Vol. 13 Issue 22, p1 

    The article reports on a takeover deal that was signed by U3 Pharma AG with Daiichi Sankyo Co. Ltd. The deal has challenged the widely-held notion that the traditional venture capital model is broken. Since its formation in 2001, U3 Pharma had already raised an estimated €42 million in...

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Oct2008, Vol. 7 Issue 10, p9 

    The article offers news briefs related to cardiovascular system. Daiichi Sankyo Co. Ltd. announced a positive data from its DU-176b anticoagulant directly inhibiting Factor Xa study. Bristol-Myers Squibb Co. and Pfizer Inc. announce encouraging results of their Phase II dose-ranging study on...

  • Seattle Genetics Nets $4M from Daiichi Sankyo.  // Bioworld Week;7/14/2008, Vol. 16 Issue 28, p3 

    The article reports that Bothell, Washington-based Seattle Genetics Inc. has gained $4 million, a payment from a deal with Daiichi Sankyo Co. Ltd., a Japanese pharmaceutical firm. It is noted that the deal has netted Seattle Genetics $69 million for the use of its antibody-drug conjugate...

  • Japan's Daiichi exits Sun Pharma.  // FRPT- Chemical Snapshot;5/3/2015, p16 

    The article discusses the sale of all holdings of Japanese drug maker Daiichi Sankyo in Sun Pharmaceutical Industries in India following the completion of the merger of Ranbaxy based on Gurgaon and Sun Pharma in 2015.

  • Ambit to Be Acquired By Japanese Company. Meiling, Brittany // San Diego Business Journal;10/6/2014, Vol. 35 Issue 40, p6 

    The article reports on the merger agreement between San Diego, California-based Ambit Biosciences Corp. and Japan-based Daiichi Sankyo Co. Ltd. biopharmaceutical companies under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences.

  • OSI Pharmaceuticals begins phase II study of lung cancer drug Tarceva.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p17 

    Reports that OSI Pharmaceuticals Inc. has initiated a phase II randomized study of monotherapy Tarceva versus standard chemotherapy of previously untreated non-small cell lung cancer patients with a poor performance status. Mechanism of action of the drug; Design of the study.

  • COMPANY SPOTLIGHT - OSI Pharmaceuticals.  // PharmaWatch: Cancer;Dec2009, Vol. 8 Issue 12, p19 

    The article presents information about OSI Pharmaceuticals Inc. The company had total revenue of 111.45 million dollars for the third quarter of 2009 compared to 94.6 million dollars in 2008. It is engaged in the discovery, development and commercialization of molecular targeted therapies. A...

  • OSI dedicates plant.  // Chemical Market Reporter;11/24/97, Vol. 252 Issue 21, p33 

    Reports on OSI Pharmaceuticals Inc.'s dedication of an expanded medicinal, combinatorial and pharmaceutical chemistry facilities of its Aston molecules operation in Birmingham, England.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics